雷贝拉唑三联疗法治疗幽门螺杆菌感染相关性胃溃疡的疗效分析

Therapeutic Effect of Rabeprazole Triple Therapy on Helicobacter Pylori Infection-Associated Gastric Ulcer

目的探讨雷贝拉唑三联疗法治疗幽门螺杆菌感染相关性胃溃疡的疗效。方法收集至该院就诊的幽门螺杆菌感染相关性胃溃疡患者110例(2015年5月—2016年6月)作为该次的研究对象,其中对常规组(n=55)选择奥美拉唑治疗,对实验组(n=55)选择雷贝拉唑治疗,对比两组的治疗总有效率、症状积分、HP根除率。结果实验组与常规组的治疗总有效率分别为94.55%与78.18%(P<0.05);治疗后实验组腹痛、腹胀、嗳气、反酸评分分别为(0.30±0.15)分、(0.89±0.48)分、(0.71±0.35)分、(0.63±0.32)分,相比常规组均明显较低(P<0.05);两组的HP根除率均为90.91%(P>0.05)。结论对幽门螺杆菌感染相关性胃溃疡患者采取雷贝拉唑三联疗法进行治疗的效果显著,便于临床症状的有效改善,提高患者生存质量。

Objective This paper tries to explore the effect of rabeprazole triad therapy for the treatment of helicobacter pylori infection.Methods 110 cases from May 2015 to June 2016 in this hospital with helicobacter pylori infection in gastric ulcer were selected as the research objects,the normal group(n=55)adopted omeprazole treatment,the experimental group(n=55)adopted rabeprazole azole treatment,the total effective rate,symptoms integral,HP eradicate rate of the two groups were compared.Results The total effective rate of the experimental group was 94.55%and 78.18%respectively(P<0.05).After treatment,abdominal pain,abdominal distension,belching,and anti-acid scores were respectively(0.30±0.15)points,(0.89±0.48)points,(0.71±0.35)points,and(0.63±0.32)points respectively,compared with the conventional group,which was significantly lower than the conventional group(P<0.05).The HP eradication rate of both groups was 90.91%(P>0.05).Conclusion The treatment helicobacter pylori infection in patients with gastric ulcer is significantly obvious,which can improve the survival quality of patients with clinical symptoms.